Cerebrospinal fluid peptides as potential parkinson disease biomarkers

A staged pipeline for discovery and validation

Min Shi, James Movius, Romel Dator, Patrick Aro, Yanchun Zhao, Catherine Pan, Xiangmin Lin, Theo K. Bammler, Tessandra Stewart, Cyrus P. Zabetian, Elaine R. Peskind, Shu Ching Hu, Joseph Quinn, Douglas R. Galasko, Jing Zhang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Finding robust biomarkers for Parkinson disease (PD) is currently hampered by inherent technical limitations associated with imaging or antibody-based protein assays. To circumvent the challenges, we adapted a staged pipeline, starting from our previous proteomic profiling followed by high-throughput targeted mass spectrometry (MS), to identify peptides in human cerebrospinal fluid (CSF) for PD diagnosis and disease severity correlation. In this multicenter study consisting of training and validation sets, a total of 178 subjects were randomly selected from a retrospective cohort, matching age and sex between PD patients, healthy controls, and neurological controls with Alzheimer disease (AD). From ∼14,000 unique peptides displaying differences between PD and healthy control in proteomic investigations, 126 peptides were selected based on relevance and observability in CSF using bioinformatic analysis and MS screening, and then quantified by highly accurate and sensitive selected reaction monitoring (SRM) in the CSF of 30 PD patients versus 30 healthy controls (training set), followed by diagnostic (receiver operating characteristics) and disease severity correlation analyses. The most promising candidates were further tested in an independent cohort of 40 PD patients, 38 AD patients, and 40 healthy controls (validation set). A panel of five peptides (derived from SPP1, LRP1, CSF1R, EPHA4, and TIMP1) was identified to provide an area under curve (AUC) of 0.873 (sensitivity = 76.7%, specificity = 80.0%) for PD versus healthy controls in the training set. The performance was essentially confirmed in the validation set (AUC = 0.853, sensitivity = 82.5%, specificity = 82.5%). Additionally, this panel could also differentiate the PD and AD groups (AUC = 0.990, sensitivity = 95.0%, specificity = 97.4%). Furthermore, a combination of two peptides belonging to proteins TIMP1 and APLP1 significantly correlated with disease severity as determined by the Unified Parkinson's Disease Rating Scale motor scores in both the training (r = 0.381, p = 0.038)j and the validation (r = 0.339, p = 0.032) sets. The novel panel of CSF peptides, if validated in independent cohorts, could be used to assist in clinical diagnosis of PD and has the potential to help monitoring or predicting disease progression.

Original languageEnglish (US)
Pages (from-to)544-555
Number of pages12
JournalMolecular and Cellular Proteomics
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Cerebrospinal fluid
Biomarkers
Parkinson Disease
Cerebrospinal Fluid
Pipelines
Peptides
Area Under Curve
Alzheimer Disease
Sensitivity and Specificity
Proteomics
Mass Spectrometry
Mass Screening
Mass spectrometry
Computational Biology
ROC Curve
Multicenter Studies
Disease Progression
Proteins
Monitoring

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry

Cite this

Cerebrospinal fluid peptides as potential parkinson disease biomarkers : A staged pipeline for discovery and validation. / Shi, Min; Movius, James; Dator, Romel; Aro, Patrick; Zhao, Yanchun; Pan, Catherine; Lin, Xiangmin; Bammler, Theo K.; Stewart, Tessandra; Zabetian, Cyrus P.; Peskind, Elaine R.; Hu, Shu Ching; Quinn, Joseph; Galasko, Douglas R.; Zhang, Jing.

In: Molecular and Cellular Proteomics, Vol. 14, No. 3, 01.03.2015, p. 544-555.

Research output: Contribution to journalArticle

Shi, M, Movius, J, Dator, R, Aro, P, Zhao, Y, Pan, C, Lin, X, Bammler, TK, Stewart, T, Zabetian, CP, Peskind, ER, Hu, SC, Quinn, J, Galasko, DR & Zhang, J 2015, 'Cerebrospinal fluid peptides as potential parkinson disease biomarkers: A staged pipeline for discovery and validation', Molecular and Cellular Proteomics, vol. 14, no. 3, pp. 544-555. https://doi.org/10.1074/mcp.M114.040576
Shi, Min ; Movius, James ; Dator, Romel ; Aro, Patrick ; Zhao, Yanchun ; Pan, Catherine ; Lin, Xiangmin ; Bammler, Theo K. ; Stewart, Tessandra ; Zabetian, Cyrus P. ; Peskind, Elaine R. ; Hu, Shu Ching ; Quinn, Joseph ; Galasko, Douglas R. ; Zhang, Jing. / Cerebrospinal fluid peptides as potential parkinson disease biomarkers : A staged pipeline for discovery and validation. In: Molecular and Cellular Proteomics. 2015 ; Vol. 14, No. 3. pp. 544-555.
@article{7896c2eaa5d943d18881d93fd6ae73bc,
title = "Cerebrospinal fluid peptides as potential parkinson disease biomarkers: A staged pipeline for discovery and validation",
abstract = "Finding robust biomarkers for Parkinson disease (PD) is currently hampered by inherent technical limitations associated with imaging or antibody-based protein assays. To circumvent the challenges, we adapted a staged pipeline, starting from our previous proteomic profiling followed by high-throughput targeted mass spectrometry (MS), to identify peptides in human cerebrospinal fluid (CSF) for PD diagnosis and disease severity correlation. In this multicenter study consisting of training and validation sets, a total of 178 subjects were randomly selected from a retrospective cohort, matching age and sex between PD patients, healthy controls, and neurological controls with Alzheimer disease (AD). From ∼14,000 unique peptides displaying differences between PD and healthy control in proteomic investigations, 126 peptides were selected based on relevance and observability in CSF using bioinformatic analysis and MS screening, and then quantified by highly accurate and sensitive selected reaction monitoring (SRM) in the CSF of 30 PD patients versus 30 healthy controls (training set), followed by diagnostic (receiver operating characteristics) and disease severity correlation analyses. The most promising candidates were further tested in an independent cohort of 40 PD patients, 38 AD patients, and 40 healthy controls (validation set). A panel of five peptides (derived from SPP1, LRP1, CSF1R, EPHA4, and TIMP1) was identified to provide an area under curve (AUC) of 0.873 (sensitivity = 76.7{\%}, specificity = 80.0{\%}) for PD versus healthy controls in the training set. The performance was essentially confirmed in the validation set (AUC = 0.853, sensitivity = 82.5{\%}, specificity = 82.5{\%}). Additionally, this panel could also differentiate the PD and AD groups (AUC = 0.990, sensitivity = 95.0{\%}, specificity = 97.4{\%}). Furthermore, a combination of two peptides belonging to proteins TIMP1 and APLP1 significantly correlated with disease severity as determined by the Unified Parkinson's Disease Rating Scale motor scores in both the training (r = 0.381, p = 0.038)j and the validation (r = 0.339, p = 0.032) sets. The novel panel of CSF peptides, if validated in independent cohorts, could be used to assist in clinical diagnosis of PD and has the potential to help monitoring or predicting disease progression.",
author = "Min Shi and James Movius and Romel Dator and Patrick Aro and Yanchun Zhao and Catherine Pan and Xiangmin Lin and Bammler, {Theo K.} and Tessandra Stewart and Zabetian, {Cyrus P.} and Peskind, {Elaine R.} and Hu, {Shu Ching} and Joseph Quinn and Galasko, {Douglas R.} and Jing Zhang",
year = "2015",
month = "3",
day = "1",
doi = "10.1074/mcp.M114.040576",
language = "English (US)",
volume = "14",
pages = "544--555",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "3",

}

TY - JOUR

T1 - Cerebrospinal fluid peptides as potential parkinson disease biomarkers

T2 - A staged pipeline for discovery and validation

AU - Shi, Min

AU - Movius, James

AU - Dator, Romel

AU - Aro, Patrick

AU - Zhao, Yanchun

AU - Pan, Catherine

AU - Lin, Xiangmin

AU - Bammler, Theo K.

AU - Stewart, Tessandra

AU - Zabetian, Cyrus P.

AU - Peskind, Elaine R.

AU - Hu, Shu Ching

AU - Quinn, Joseph

AU - Galasko, Douglas R.

AU - Zhang, Jing

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Finding robust biomarkers for Parkinson disease (PD) is currently hampered by inherent technical limitations associated with imaging or antibody-based protein assays. To circumvent the challenges, we adapted a staged pipeline, starting from our previous proteomic profiling followed by high-throughput targeted mass spectrometry (MS), to identify peptides in human cerebrospinal fluid (CSF) for PD diagnosis and disease severity correlation. In this multicenter study consisting of training and validation sets, a total of 178 subjects were randomly selected from a retrospective cohort, matching age and sex between PD patients, healthy controls, and neurological controls with Alzheimer disease (AD). From ∼14,000 unique peptides displaying differences between PD and healthy control in proteomic investigations, 126 peptides were selected based on relevance and observability in CSF using bioinformatic analysis and MS screening, and then quantified by highly accurate and sensitive selected reaction monitoring (SRM) in the CSF of 30 PD patients versus 30 healthy controls (training set), followed by diagnostic (receiver operating characteristics) and disease severity correlation analyses. The most promising candidates were further tested in an independent cohort of 40 PD patients, 38 AD patients, and 40 healthy controls (validation set). A panel of five peptides (derived from SPP1, LRP1, CSF1R, EPHA4, and TIMP1) was identified to provide an area under curve (AUC) of 0.873 (sensitivity = 76.7%, specificity = 80.0%) for PD versus healthy controls in the training set. The performance was essentially confirmed in the validation set (AUC = 0.853, sensitivity = 82.5%, specificity = 82.5%). Additionally, this panel could also differentiate the PD and AD groups (AUC = 0.990, sensitivity = 95.0%, specificity = 97.4%). Furthermore, a combination of two peptides belonging to proteins TIMP1 and APLP1 significantly correlated with disease severity as determined by the Unified Parkinson's Disease Rating Scale motor scores in both the training (r = 0.381, p = 0.038)j and the validation (r = 0.339, p = 0.032) sets. The novel panel of CSF peptides, if validated in independent cohorts, could be used to assist in clinical diagnosis of PD and has the potential to help monitoring or predicting disease progression.

AB - Finding robust biomarkers for Parkinson disease (PD) is currently hampered by inherent technical limitations associated with imaging or antibody-based protein assays. To circumvent the challenges, we adapted a staged pipeline, starting from our previous proteomic profiling followed by high-throughput targeted mass spectrometry (MS), to identify peptides in human cerebrospinal fluid (CSF) for PD diagnosis and disease severity correlation. In this multicenter study consisting of training and validation sets, a total of 178 subjects were randomly selected from a retrospective cohort, matching age and sex between PD patients, healthy controls, and neurological controls with Alzheimer disease (AD). From ∼14,000 unique peptides displaying differences between PD and healthy control in proteomic investigations, 126 peptides were selected based on relevance and observability in CSF using bioinformatic analysis and MS screening, and then quantified by highly accurate and sensitive selected reaction monitoring (SRM) in the CSF of 30 PD patients versus 30 healthy controls (training set), followed by diagnostic (receiver operating characteristics) and disease severity correlation analyses. The most promising candidates were further tested in an independent cohort of 40 PD patients, 38 AD patients, and 40 healthy controls (validation set). A panel of five peptides (derived from SPP1, LRP1, CSF1R, EPHA4, and TIMP1) was identified to provide an area under curve (AUC) of 0.873 (sensitivity = 76.7%, specificity = 80.0%) for PD versus healthy controls in the training set. The performance was essentially confirmed in the validation set (AUC = 0.853, sensitivity = 82.5%, specificity = 82.5%). Additionally, this panel could also differentiate the PD and AD groups (AUC = 0.990, sensitivity = 95.0%, specificity = 97.4%). Furthermore, a combination of two peptides belonging to proteins TIMP1 and APLP1 significantly correlated with disease severity as determined by the Unified Parkinson's Disease Rating Scale motor scores in both the training (r = 0.381, p = 0.038)j and the validation (r = 0.339, p = 0.032) sets. The novel panel of CSF peptides, if validated in independent cohorts, could be used to assist in clinical diagnosis of PD and has the potential to help monitoring or predicting disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84924289947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924289947&partnerID=8YFLogxK

U2 - 10.1074/mcp.M114.040576

DO - 10.1074/mcp.M114.040576

M3 - Article

VL - 14

SP - 544

EP - 555

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 3

ER -